Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000247615 | SCV000312152 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Illumina Laboratory Services, |
RCV000361137 | SCV000383373 | likely benign | Charlevoix-Saguenay spastic ataxia | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001084224 | SCV000562820 | benign | Spastic paraplegia | 2025-01-21 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000247615 | SCV001476018 | benign | not specified | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000676370 | SCV001948166 | benign | not provided | 2019-03-21 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001848027 | SCV002105000 | benign | Hereditary spastic paraplegia | 2021-11-05 | criteria provided, single submitter | clinical testing | |
PROSPAX |
RCV000361137 | SCV005061959 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2022-01-01 | criteria provided, single submitter | research | |
Breakthrough Genomics, |
RCV000676370 | SCV005219360 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000676370 | SCV000802146 | benign | not provided | 2017-08-22 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000361137 | SCV001453561 | benign | Charlevoix-Saguenay spastic ataxia | 2020-09-16 | no assertion criteria provided | clinical testing |